Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Biotechnology

Healthcare
$5.30 -2.45%

-$0.27 today

Market cap
$430.84M
Beta
0.51
P/E (TTM)
-5.6
EPS (TTM)
-$1.92
52W Low $7.61High $18.31

Volume 1.67M

Average 1.21M

Returns on capital

Phathom Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

50.5%

avg 58.2%

ROIC

-125.2%

avg -92.3%

ROA

-85.4%

avg -85.8%

Analysis

ROE is currently the strongest return metric at 50.5% versus its period average of 58.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David A. Socks

Co-FounderUSD 1.95M5117.50K0.02%

Azmi Nabulsi

Co-FounderUSD 1.95M6655.00K0.07%

Steven L. Basta

Chief Executive Officer, President & DirectorUSD 1.17M60373.31K0.47%

Anne Marie Cook

Chief Legal Officer & Corporate SecretaryUSD 663.41K6488.66K0.11%

Sanjeev Narula

Chief Financial & Business OfficerUSD 644.29K65214.72K0.27%

Robert Breedlove

Vice President of Finance & Principal Accounting Officer————

Nancy R. Phelan

Senior Vice President of Marketing & Analytics—57——

Bill Aprea

Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer————

Eric Sciorilli

Director of Business Development & Investor Relations————

Jonathan Bentley

Senior Vice President and Head of Sales, Operations & Training————

Paul Cocja

Chief People Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
+40.1% (5yr)4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Forward estimates point to Revenue at +40.1% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Phathom Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

Questions

Management questions

Common questions about PHAT's management, answered from reported figures.

Who manages PHAT?

Phathom Pharmaceuticals, Inc. (PHAT) lists 11 active executives. The top listed executive is David A. Socks, Co-Founder.

Are PHAT insiders buying or selling?

Recent insider activity shows net selling of $30.69M.